Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SusmedTSE:4263 -4.30%73 3-Year RORE % is 36.24 as of Dec. 2025. GuruFocus rates TSE:4263 with a GF Score™ of 73/100 and a GF Value™ of 円846.73 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 602 Healthcare Providers & Services companies, Susmed ranks better than 80.23% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Susmed's 3-Year RORE % for the quarter that ended in Dec. 2025 was 36.24%.
The industry rank for Susmed's 3-Year RORE % or its related term are showing as below:
TSE:4263's 3-Year RORE % is ranked better than 80.23% of 602
companies
in the Healthcare Providers & Services industry
Industry Median: 0.35
vs TSE:4263: 36.24
Susmed (TSE:4263) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Susmed 3-Year RORE % Related Terms
Susmed 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Susmed's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4263 vs VEEV, BTSG, TEM: 3-Year RORE % Comparison
For the Health Information Services subindustry, Susmed's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Susmed 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Susmed's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Susmed's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Susmed (TSE:4263) has a 3-Year RORE % of 36.24 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Susmed and its competitors. According to the industry distribution chart, Susmed ranks #119 out of 602 companies in the Healthcare Providers & Services industry, placing it in the top 19.8%.
Is Susmed's 3-Year RORE % too high?
Susmed's current 3-Year RORE % is 36.24. The Healthcare Providers & Services industry median 3-Year RORE % is 0.35. Susmed's value of 36.24 is 10254.3% above this industry median. Based on the distribution chart, Susmed ranks #119 out of 602 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Susmed has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's 3-Year RORE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Susmed ranks #119 out of 602 companies for 3-Year RORE %. This places Susmed in the top 20% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.35. Susmed's value of 36.24 is 10254.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.35, based on 602 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Susmed's current 3-Year RORE % of 36.24 is 10254.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Susmed and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Susmed's current 3-Year RORE % is 36.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円846.73, compared to a current price of 円690.00 — trading 18.5% below its estimated fair value. The current 3-Year RORE % is 36.24 and 10254.3% above the Healthcare Providers & Services industry median of 0.35. Susmed's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Susmed (TSE:4263), the current 3-Year RORE % is 36.24 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Susmed (TSE:4263) Overvalued in 2026?
Based on GuruFocus' analysis, Susmed stock appears to be undervalued.
The current stock price of 円690.00 is trading 18.5% below its estimated GF Value™ of 円846.73.
GuruFocus considers Susmed to be Modestly Undervalued.
Key valuation signals for TSE:4263:
3-Year RORE %: 36.24
GF Value™: 円846.73 vs. price of 円690.00 (18.5% below fair value)
Industry Position: 10254.3% above the Healthcare Providers & Services median (#119 of 602)
No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
73GF Score
Get the complete analysis for TSE:4263
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4263 has been successfully added to your 
